Background: Type 3 innate lymphoid cells (ILC3s) are involved in maintenance of mucosal homeostasis; however, their role in immunoregulation has been unknown. Immature transitional regulatory B (itBreg) cells are innate-like B cells with immunosuppressive properties, and the in vivo mechanisms by which they are induced have not been fully clarified. Objective: We aimed to investigate the ILC3-B-cell interaction that probably takes place in human tonsils. Methods: ILC3s were isolated from peripheral blood and palatine tonsils, expanded, and cocultured with naive B cells. Tonsillar ILC3s and regulatory B cells were visualized with immunofluorescence histology. ILC3 frequencies were measured in tonsil tissue of allergic and nonallergic patients and in peripheral blood of allergic asthmatic patients and healthy control subjects. Results: A mutually beneficial relationship was revealed between ILC3s and B cells: ILC3s induced IL-15 production in B cells through B cell-activating factor receptor, whereas IL-15, a potent growth factor for ILC3s, induced CD40 ligand (CD40L) expression on circulating and tonsillar ILC3s. IL-15-activated CD40L
1 ILC3s helped B-cell survival, proliferation, and differentiation of IL-10-secreting, PD-L1-expressing functional itBreg cells in a CD40L-and B cell-activating factor receptor-dependent manner. ILC3s and regulatory B cells were in close connection with each other in palatine tonsils. ILC3 frequency was reduced in tonsil tissue of allergic patients and in peripheral blood of allergic asthmatic patients. Conclusion: Human CD40L
1 ILC3s provide innate B-cell help and are involved in an innate immunoregulatory mechanism through induction of itBreg cell differentiation, which takes place in palatine tonsils in vivo. This mechanism, which can contribute to maintenance of immune tolerance, becomes insufficient in allergic diseases. Exploration of the diversity of innate lymphoid cells (ILCs) 1, 2 and ''innate-like'' B-cell subsets with regulatory potential 3 has substantially redrawn the picture of immune homeostasis and tissue inflammation. Despite detailed descriptions of the mechanisms through which ILC subsets contribute to various adaptive and innate immune processes, 2, 4 their involvement in immunoregulation has not been delineated. Retinoic acid receptor-related orphan receptor gt (RORgt)-expressing type 3 innate lymphoid cells (ILC3s) in adult mice and human subjects play a role in innate immune defense at mucosal barrier surfaces 5 and tissue regeneration after damage, [6] [7] [8] [9] mainly through secretion of their signature cytokine, IL-22. [10] [11] [12] ILC3s are also involved in limitation of pathologic adaptive immune responses against commensal bacteria in the gut. 13 ILC3s have a dedicated role in the maintenance and restoration of homeostasis at the interface of the environment and the body. 4 Among the several B-cell subsets with immunoregulatory properties that have been identified, 14 there is an immature transitional regulatory B (itBreg) cell subpopulation with the CD19
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CD1d high phenotype and IL-10-producing capacity. 15 The in vivo differentiation pathway of itBreg cells has not been fully explored thus far. 14 Recently, it has been shown that ILCs can have an influence on antibody production in mice. 16, 17 Splenic ILC3s stimulate marginal zone B cells through CD40 ligand (CD40L; CD154) and B cell-activating factor (BAFF) and help to orchestrate innate-like IgM antibody production in human subjetcs, 18 suggesting that a functional ILC-B-cell interaction takes place in vivo.
The present study describes that CD40L 1 ILC3s reside on the border of the T-cell-B-cell areas in tonsils and are in close contact with B cells in vivo. CD40L
1 ILC3s and B cells are in mutually beneficial relationship with each other because CD40L
1 ILC3s strongly support the survival and proliferation of B cells and promote IgM secretion and IL-10-producing, programmed death ligand 1 (PD-L1)-expressing itBreg cell differentiation in a CD40L-and BAFF-dependent manner, whereas B cells upregulate IL-15, a growth factor for ILC3s, on interaction with CD40L 1 ILC3s. ILC3s can contribute to the maintenance of immune tolerance through itBreg cell induction. A relative deficiency of ILC3s in patients with allergic diseases has been demonstrated.
METHODS
Peripheral blood and tonsil tissue samples
Peripheral blood samples for in vitro cell culture experiments were collected from healthy volunteers.
Human palatine tonsil tissue samples of 8 allergic and 11 nonallergic subjects were obtained from hospitals of Davos and Chur, Switzerland. Patients underwent elective tonsillectomy because of hypertrophic and obstructive tonsils. Patients with a clinical history of atopic dermatitis, food allergy, or allergic asthma, together with positive skin prick test responses or specific IgE measurements, were included in the allergic group. Only the samples of nonallergic subjects were used for in vitro ILC3-B-cell coculture experiments. The prevalence of ILC3s and the IL15 mRNA expression of [3] [4] were included in the study at their arrival to the hospital (Hochgebirgsklinik, Davos-Wolfgang, Switzerland) before the introduction of any new medication or starting of the rehabilitation program. The patients had atopy (positive skin prick test response or specific IgE measurement), and asthma symptoms were related to the relevant allergen (eg, exacerbated during the pollen season or reduced in a house dust mite-free environment). All patients received medium-or high-dose inhaled corticosteroid and long-acting b 2 -agonist treatment and have not received systemic glucocorticoids in last 4 month. Patients who fulfill these inclusion criteria were selected by a pulmonologist. Twenty-three age-matched healthy volunteers served as control subjects for comparison of circulating ILC3 levels. All sample preparation and analyses were performed within 3 hours of blood withdrawal. The leftover PBMC samples that were not used for the experiments were frozen and stored in a biobank. Therefore, altogether, 17 samples from healthy subjects and 17 samples from patients with allergic asthma were available for later itBreg and regulatory T (Treg) cell measurements.
The study was approved by the Cantonal Ethics Committee of Graub€ unden, and informed consent was obtained from all donors.
Flow cytometry and cell sorting
Flow cytometric data were acquired on Galios (Beckman Coulter, Fullerton, Calif), FACSAria II (Aria III upgrade), and LSRFortessa (Becton Dickinson, San Jose, Calif) instruments and analyzed with Kaluza software (Beckman Coulter). To improve the efficiency of ILC3 sorting, the PBMC samples were first depleted of monocytes, T cells, and B cells, and tonsillar mononuclear cell (TMC) samples were depleted of B cells. For this purpose, the cells were labeled with magnetic microbead-bound anti-CD14, anti-CD3, and anti-CD19 antibodies (or just with anti-CD19 antibodies for TMCs), and the positive cell populations were depleted by means of immunomagnetic separation (Auto-MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). We used the remaining cells for ILC3 sorting. Lineage markers (Lin) were CD3, CD19, CD20, CD14, CD34, CD11c, and CD94 for ILC3 sorting experiments. Before naive B-cell sorting, monocytes and T cells were depleted from the samples. ILC3s and naive B cells were sorted on a FACSAria II instrument to high purity (> _98%).
Establishment of the CD40L
1 ILC3 cell line, as well as CD40L
1 ILC3-B-cell cocultures 
Statistical analysis
Data were analyzed with Statistica 7.0 (TIBCO Software, Palo Alto, Calif) and GraphPad Prism (GraphPad Software, La Jolla, Calif) software. The Student t test or 1-way ANOVAwith the Bonferroni post hoc test were used for parametric variables, and the Mann-Whitney U test or Kruskal-Wallis test with the Dunn post hoc test were used for nonparametric variables, as appropriate.
Interrelations of the various cell populations were analyzed by using Spearman rank correlation. Sample sizes were chosen based on previous studies. The only reason for data exclusion was the technical error of the cell culture. All results are expressed as means 6 SEMs.
Further details of the methods are described in this article's Online Repository at www.jacionline.org.
RESULTS
ILC3s of peripheral blood and tonsil tissue acquire CD40L-expression in response to IL-15 IL-15 is known to induce ILC proliferation 2, 20 ; however, its role in ILC3 activation and differentiation has not been clear thus far. Therefore, as a novel approach, we expanded ILC3s with IL-15 (for 20 days). Blood-derived ILC3s differentiated into 3 major cell populations on IL-15 stimulation (Fig 1, A) (Fig 3, A) and B-cell proliferation (Fig 3, B) were analyzed on day 12 by using flow cytometry. A viability dye, e-450, was used to discriminate between living and dead cells. Proliferation rate of the B cells was assessed by using flow cytometric analysis of CFSE dilution in the dividing cells and calculation of the proliferative in- (Fig 1, B) .
ILC3s are CD45 1 cells of hematopoietic origin and migrate consequently from the bone marrow to secondary lymphoid organs and mucosa-associated lymphoid tissues through the bloodstream. ILC3s represent a rare cell subset in both blood and palatine tonsils. Lin Fig E1, A and B, in this article's Online Repository at www.jacionline.org) were sorted and expanded for in vitro functional experiments. Freshly isolated ILC3s expressed high levels of RORC mRNA encoding RORgt, the signature transcription factor of the ILC3s (see Fig E1, C) .
Tonsillar epithelial cells and myeloid dendritic cells (mDCs) express high levels of IL15 mRNA (Fig 1, C) , and they can be local sources of this growth factor for ILC3s. Circulating ILC3s did not express the natural killer (NK) receptor NKp44 (CD336) on their surfaces. Although primary tonsillar ILC3s were predominantly NKp44 1 , blood-derived ILC3s acquired this mucosal phenotype in response to IL-15 (Fig 1, D) .
In the next step we aimed to determine the key characteristics of CD40L
1 ILC3s to provide evidence that they are indeed in the ILC3 lineage. First, CD40L
1 ILC3s expressed high levels of RORC mRNA (Fig 1, E) , as well as RORgt protein (Fig 1, F) .
Second, CD40L
1 ILC3s secreted high amounts of IL-22 in response to IL-23 (Fig 1, G) . Finally, CD40L
1 ILC3s did not express GATA3 mRNA (see Fig E2, A, in this article's Online Repository at www.jacionline.org) or TBX21 mRNA (encoding T-bet; Fig E2, B) , representing the characteristic transcription factors of type 2 ILCs and type 1 ILCs, respectively. 2 In addition, tonsillar ILC3s expressed the mRNA encoding CD40L (CD40LG) directly after isolation of cells without any culture (Fig 1, H) , and CD40L protein was also shown on the surfaces of ILC3s ex vivo (Fig 1, I ). CD40L
1 ILC3s did not express granzyme B or perforin, the characteristic cytotoxic enzymes of cNK cells (see Fig E2, C and D).
CD40L
1 ILC3s reside at the interface between T-and B-cell areas in palatine tonsils and support B-cell survival, proliferation, and differentiation Our next focus was to delineate the in vivo function of CD40L 
ILC3s. The anatomic localization of CD40L
1 ILC3s in human palatine tonsils has implications for their functional properties. ILC3s typically reside in the interfollicular area in secondary lymphoid organs. 13 In addition to T H 17 cells, only ILC3s express RORgt in tonsil tissue. Therefore we visualized with immunofluorescence histology that RORgt 1
CD3
2 ILC3s were localized particularly at the interface between T-and B-cell areas in tonsils and were in close contact with CD20 Considering the localization of CD40L 1 ILC3s in tonsils, it can be expected that the interaction of CD40L
1 ILC3s and B cells takes place in vivo. CD40L
1 ILC3s (and CD40L 2 ILC3s) express Toll-like receptor 9 (TLR9; see Fig E5, A, in this article's Online Repository at www.jacionline.org), and thus ILC3s and B cells 21 are both able to respond to unmethlyated CpG oligodeoxynucleotides. CD40L can be cleaved from the cell surface and released by CD40L
1 cells, such as activated T H cells. Soluble CD40L (sCD40L) has a similar B cell-stimulatory effect to membrane-bound CD40L.
22 CD40L 1 ILC3s also released sCD40L, and this was further enhanced by CpG (see Fig E5, B), whereas surface expression of CD40L did not change in response to CpG stimulation (see Fig E5, C) .
To investigate ILC3-B-cell interaction in detail, we cocultured CD40L 1 and CD40L 2 ILC3s with B cells. We used autologous CD19
1 naive B cells of high purity (see Fig E6, A and B, in this article's Online Repository at www.jacionline.org). This B-cell pool includes both immature transitional and mature naive B cells. 15, 23 We demonstrated that both blood-and tonsil-derived CD40L
1
ILC3s supported B-cell survival and proliferation in a dose-dependent manner (Figs 2, A-C, and 3, A and B, respectively). IgM production was also strongly induced by CD40L
1 ILC3s in cocultures. This effect was attributable specifically to ILC3s because CD40L stimulation alone, as provided by L cells (irradiated human CD40L-expressing mouse fibroblasts), was not sufficient to induce high IgM production (Fig 2, D) .
CD40L
1 ILC3-mediated innate B-cell help is specifically focused on immature transitional B cells transitional B (itB) cells (defined in Fig 4, A) . The itB cells also proliferated in these cocultures, although slower than IgM single-positive B cells (Fig 4, B) . In CD40L 1 ILC3 cocultures there was a small but significant increase in the relative abundance of itB cells already on day 6 compared with CD40L 2 ILC3 cocultures, L-cell cocultures, and B cells alone, and this difference became prominent on day 12 (Fig 4, C) ILC3s provided innate, T cell-independent help to itB cells. The presence of itB cells in TMCs was confirmed right after isolation without any in vitro stimulation or cell culture (Fig 4, D) .
1 ILC3s induce development of IL102secreting PD-L1
1 regulatory B cells
Secretion of IL-10, IL-1 receptor antagonist (IL-1ra), and IL-6 dose-dependently increased in parallel to the increasing proportion of CD40L
1 ILC3s in B-cell cocultures. The balance between regulatory (IL-10 and IL-1ra) and proinflammatory (IL-6) cytokines tilted remarkably toward the regulatory direction in CD40L
1 ILC3-B-cell cocultures, suggesting development of regulatory B (Breg) cells. In contrast, this balance skewed toward the proinflammatory cytokine IL-6 in B-cell-L-cell cultures (Fig 5, A) . Our data clearly demonstrated that the IL-10-producing B-cell differentiation was dose-dependently related to the relative abundance of CD40L 1 ILC3s in blood-derived cocultures (Fig 5, B) and was efficiently induced in tonsil-derived CD40L
1 ILC3-B-cell cocultures (Fig 3, C) .
Interestingly, the IL-10-producing B cells in CD40L 1 ILC3-B-cell cocultures were IL-6 1 IL-10 1 on day 6, probably because of the initial CpG stimulation, but became IL-6 -IL-10 1 on day 12 (Fig 5, C) (Fig 5, D) .
Considering that B cells can contact both the abundant T cells and the relatively rare ILC3s in the tissues, we aimed to examine the difference between these 2 interactions to define the specific function of CD40L 1 ILC3s. T cells were much weaker in the support of long-term survival of itB cells compared with CD40L
1 ILC3s because on day 12 a lower relative abundance of itB cells was observed within both all B cells and IL-10 1 B cells in T-cell-B-cell cocultures compared with that in CD40L
1 ILC3-B-cell cocultures (Fig 5, E) .
As an additional marker of regulatory phenotype, IL-10 1 B cells expressed PD-L1 on their surfaces (Fig 5, F) .
To prove that the developed IL-10 1 B cells were bona fide Breg cells, B cells were isolated from CD40L
1 ILC3 cocultures on day 12 and tested in a suppression assay. CD40L
1 ILC3 coculture-derived Breg cells were able to suppress tetanus toxoid-induced T-cell proliferation in a dose-dependent manner. Their suppressive efficiency was comparable with that of Treg cells or rhIL-10 (10 ng/mL) and was dependent on IL-10 because it was inhibited by anti-IL-10 receptor blocking antibody (Fig 5, G) .
Role of CD40L in ILC3-B-cell interaction
B-cell viability, IL-10
1 Breg cell differentiation, both regulatory (IL-10 and IL-1ra) and proinflammatory (IL-6) cytokine production, and IgM secretion were strongly dependent and proliferative capacity was, to a lesser extent, dependent on ILC3-provided CD40L-mediated help. This was suggested by the observation that the absence of CD40L from ILC3 surfaces (in case of CD40L 2 ILC3s) or inhibition of CD40-CD40L interaction by a neutralizing anti-CD40L antibody (Fig 6, A-C) , as well as the physical prevention of cell-cell contact in transwell plate cocultures (Fig 6, D and E) , resulted in a reduction of the B cell-supporting effects of ILC3s. Meanwhile, ILC3 viability was not affected by the physical separation of B cells in transwell cocultures (Fig 6, D) . Moreover, the specific itB cell-inducing effects of CD40L 1 ILC3s still persisted in part, even in the absence of cell-cell contact (in transwell cocultures; Fig 6, F) .
BAFF and IL-15 are key players of bilateral ILC3-B-cell interaction
CD40L
1 ILC3s were able to produce BAFF in response to IFN-g (Fig 7, A) . BAFF is a key cytokine of B-cell maturation 24 and survival. 25 Substantial amounts of IFN-g are secreted spontaneously in tonsils, 26 which can be further increased during immune responses against invading microorganisms (eg, in bacterial infection) and thus probably able to induce BAFF production in ILC3s in vivo. Moreover, B cells upregulated IL15 mRNA expression on interaction with CD40L 1 ILC3s in cocultures (Fig 7, B) . IL-15 production of B cells was induced only by CD40L
1 ILC3s (not by L cells) and was inhibited by anti-BAFF receptor (aBAFF receptor) blocking antibody (Fig 7, C) . The growth and survival of ILC3s depended on IL-15 because they ceased to proliferate and died off within 6 days after withdrawal of this cytokine from the culture medium (see second column in Fig 7, D) . To analyze the ILC3-supporting effects of B cells, we compared ILC3 survival in ILC3-only cultures and B-cell cocultures in the presence or absence of IL-15 supplementation. ILC3 survival was significantly greater in B-cell cocultures compared with ILC3-only cultures without IL-15 (Fig 7, D) .
Blocking of BAFF receptor did not influence the B-cell viability, proliferation, IL-10-producing B-cell differentiation, and cytokine and IgM production in CD40L 1 ILC3-B-cell cocultures (see Fig E7 in this article' s Online Repository at www.jacionline.org). However, the itB cell-inducing effects of CD40L 1 ILC3s were mediated, at least in part, through BAFF-BAFF receptor interaction because the relative abundance of itB cells was reduced by aBAFF receptor in cocultures (Fig 7, E) .
To further clarify the role of BAFF in IL-15 production, we stimulated tonsillar naive B cells with BAFF or CpG alone or both together. BAFF plus CpG stimulation induced IL15 mRNA expression (Fig 7, F) and IL-15 production (Fig 7, G ) were visualized with immunofluorescence histology. These cells were in close contact with each other (Fig 8, A) , were found in niches of regulatory cells that also harbor numerous CD3 1
IL-10
1 Treg cells, and localized in the interfollicular area of the palatine tonsils (see Fig E8, A, in this article's Online Repository at www.jacionline.org).
Relative abundance of ILC3s is reduced in patients with allergic disease
The relative frequency of ILC3 cells was lower in TMC lymphocytes isolated from palatine tonsil tissue of allergic compared with nonallergic subjects (Fig 8, B) . Both ILC3s and itBreg cells were less abundant in the peripheral blood of patients with allergic asthma compared with that of healthy control subjects (Fig 8, C , and see Fig E8, B) , but Treg cell numbers were equal in the 2 groups (see Fig E8, C) . Percentages of ILC3s positively correlated with those of itBreg cells (Fig 8,  D) , whereas Treg cell percentages did not correlate with either ILC3 or itBreg cell percentages (see Fig E8, D and E) .
DISCUSSION
For the first time, the present study provides evidence that activated CD40L-expressing ILC3s (CD40L Fig E1, B) . *P < .05, allergic versus nonallergic subjects. C, Percentage of ILC3s in peripheral blood lymphocytes of patients with allergic asthma and healthy control subjects (ILC3s were gated according to the strategy shown in Fig E1, A) ILC3s strongly support naive B-cell survival and proliferation in vitro. The anatomic localization of ILC3s in human palatine tonsils enables them to encounter and contact B cells in vivo. CD40L expression on ILC3 surfaces makes the interaction with B cells almost self-evident because of the well-established essential role of CD40-CD40L interaction in B-cell activation, differentiation, and survival. 22, 28 Moreover, both ILC3s and B cells express TLR9, and we demonstrated that sCD40L release and thus the B cell-fostering capacity of CD40L 1 ILC3s were increased on stimulation with CpG. In addition to CD40L expression, ILC3s are also able to produce BAFF, 29 another B cell-stimulating factor. 24 Consequently, both spatial and contextual factors suggest that ILC3-B-cell interaction takes place in tonsils in vivo. have a remarkable immunoregulatory capacity 15, [30] [31] [32] [33] and are deficient and/or functionally impaired in patients with autoimmune diseases (eg, systemic lupus erythematosus 15 and rheumatoid arthritis 32 ). Expression of PD-L1, an inhibitory costimulatory molecule, can also contribute to the immunoregulatory functions of Breg cells. 34, 35 Increasing evidence suggests 4 that ILC3s play a key role in mucosal homeostasis and immunoregulation through IL-22 production, 5, 8, 11, 12 promotion of natural IgM secretion, 18 limitation of immune responses against commensal bacteria, 13 inhibition of T H 17-mediated intestinal inflammation, 36 and restoration of lymphoid tissue integrity after destructive infection 7 ; consequently, the demonstrated ability of CD40L
1
ILC3s to promote itBreg cell differentiation fits well with the regulatory image 4 of ILC3s. B cells are known to produce IL-6 in response to innate stimulation with CpG, and cytokine secretion is further increased in the presence of CD40L. 37 These stimuli also induce secretion of the inhibitory cytokines IL-10 and IL-1ra; however, typically, they do not reach high levels in vitro. Here we demonstrated that CD40L 1 ILC3s were potent inducers of cytokine production by B cells. The seemingly contradictory activation state of the B cells (ie, parallel production of IL-6 and IL-10) is a subject of long-standing debate. A recent study suggested an explanation for this: IL-6 could be essential for the IL-10-producing B-cell development. 38 Although the exact cellular sources of IL-6 have not been specified in that study, it has been shown that massive IL-6 production from mesenteric lymph node lymphocytes and splenocytes, most probably including B cells and ILC3s, is required for normal Breg cell development. In our CD40L
1 ILC3-B-cell cocultures, both cell types produced IL-6 in the early phase on day 6 after activation with CpG, and this might facilitate differentiation of IL-10 1
IL-6
2 Breg cells detected on day 12.
We showed that CD40-CD40L interaction plays a pivotal role in ILC32B-cell communication because it was crucial for CD40L
1 ILC32induced Breg cell development, as well as for cytokine and IgM production. ILC3-derived BAFF can also participate in itBreg cell induction in human tonsils because it is an important cytokine for ILC32B-cell interplay. BAFF participates in T cell-independent help provided by dendritic cells (DCs), macrophages, neutrophils and ILC3s to splenic marginal zone B cells and plasma cells, 18 and it is known to induce IL-10-producing Breg cells in mice.
39 CD40L 1 ILC3s could produce BAFF; however, we could not detect a proliferation-inducing ligand (APRIL) in these cells. We observed that CD40L
1 ILC3s exerted an itB cell-inducing effect, even in the absence of cell-cell contact (in transwell cocultures), and consequently, this can be partially mediated by soluble factors, including BAFF. BAFF signaling through BAFF receptor (TNFRSF13C) has a key role in B-cell maturation because transitional, follicular, and marginal zone B-cell numbers are strongly reduced in BAFF receptor-deficient mice. 40 We found that the itB cell-inducing effect of ILC3s was also BAFF dependent because it was reduced by neutralization of BAFF receptor.
Tonsils have been identified as important mucosal sites of immune tolerance 41 at which generation of functional allergen-specific Treg cells occurs. We demonstrated that RORgt
1
CD3
2 ILC3s and CD20 1 ILC3s might be involved in maintenance of immune tolerance in tonsils through induction of functional itBreg cells. These cells can contribute to suppression of T-cell responses both through cell-cell contact via PD-L1 and via secreted IL-10. These mechanisms can also play a role in immune tolerance induction during successful sublingual immunotherapy. 42, 43 Absolute numbers of Treg cells and expression levels of forkhead box protein 3 in these cells are dependent on IL-10 production by B cells. Modulation of Treg cell frequencies in vivo is exclusively restricted to transitional 2 marginal zone precursor Breg cells in mice. 44 In addition, human itBreg cells are able to induce Treg cells in vitro. 45 Of note, worm infection-induced CD1d high IL-10-producing Breg cells can prevent and reverse airway inflammation in allergized mice by inducing recruitment of Treg cells to the lung. 46 Treg cell percentages were not lower in allergic asthmatic patients and did not correlate with either ILC3 or itBreg cell counts, suggesting that peripheral blood Treg cell levels might not mirror immunoregulatory status and that these cells can be influenced by multiple factors.
Adoptive transfer of itBreg cells can ameliorate allergic airway inflammation and hyperresponsiveness in a mouse model of allergic asthma in an IL-10-dependent manner. 47 The relative proportion of various Breg cell subsets within B cells was found to be reduced in patients with allergic diseases (allergic rhinitis 48 and allergic asthma 49 ), and the frequency of IL-10-producing, antigen-specific B cells increased after allergen-specific immunotherapy. 35 We demonstrated that ILC3s comprised a significantly smaller fraction of tonsillar lymphocytes in allergic compared with nonallergic subjects. The frequency of ILC3s, expressed as a percentage of all CD45 1 cells, has been reported to be unaltered in patients with mild asthma (GINA step 1) with confounding allergic rhinoconjunctivitis compared with nonallergic control subjects. 50 However, we found significantly reduced circulating ILC3 numbers within all lymphocytes in highly selected patients with moderate-to-severe allergic asthma (GINA steps 3-4) compared with those in healthy control subjects. There was a significant positive correlation between peripheral blood ILC3 and itBreg cell percentages, and the lower ILC3 levels in allergic asthmatic patients were accompanied by lower itBreg cell counts.
It was suggested by mouse models that IL-15 can have a protective role in patients with allergic diseases. 51, 52 We showed that CpG-and BAFF-induced IL-15 production is deficient in tonsillar naive B cells of allergic patients. This might represent a mechanism that contributes to reduction in the size of the circulating ILC3 pool.
Collectively, our experimental results indicate a strong itBreg cell-inducing capacity of activated ILC3s, and therefore the reduced ILC3 levels can contribute to insufficient Breg cell-mediated immune tolerance in patients with various allergic diseases, including allergic asthma.
In conclusion, we have described here a novel innate immunoregulatory function of CD40L 1 ILC3s, an activated form of ILC3s. CD40L
1 ILC3s provide extrafollicular, T cellindependent B-cell help in palatine tonsils and induce itBreg cell development. This mechanism can contribute to the maintenance of immune tolerance to innocuous antigens and becomes insufficient in allergic patients. Further investigation is required to explore the possibility of the therapeutic interventions targeting ILC3-B-cell interaction in patients with allergic diseases. 
METHODS
Isolation of cells
PBMCs were isolated by using Ficoll (Biochrom, Cambridge, United Kingdom) density gradient centrifugation within 3 hours of sample collection. TMCs and tonsillar mDCs and pDCs were isolated, as previously described by us. E1 Briefly, single-cell suspensions of TMCs were isolated by means of mechanical disruption. Tissues were chopped and ground with RPMI 1640 medium (Sigma, St Louis, Mo) through a 40-mm mesh. After several washing steps with medium, cells were purified by means of centrifugation on a Ficoll density gradient.
For tonsillar T-and B-cell preparation, TMC samples were labeled with magnetic microbead-bound anti-CD3 and anti-CD19 antibodies, respectively, and positive cell populations were isolated by means of immunomagnetic separation.
Tonsillar DCs were isolated from TMCs by means of negative selection with immunomagnetic separation (AutoMACS; Miltenyi Biotec) by using magnetic microbead-bound anti-CD3, anti-CD19, anti-CD16, anti-CD14, and anti-CD326 antibodies in the presence of Fc receptor blocking reagent (Miltenyi Biotec). Tonsillar mDCs were obtained from tonsillar DCs by using the positive selection by CD1c (BDCA-1)
1 DC isolation kit (Miltenyi Biotec) supplemented in the first incubation step with anti-CD11c biotinylated antibody. The negative fraction was used for isolation of tonsillar pDCs by means of positive selection by using the CD304 (BDCA-4/Neuropilin-1) microbead kit (Miltenyi Biotec). Tonsillar epithelial cells were isolated, according to a previously described protocol. E2 Briefly, epithelium was cut off the tonsil tissue, cut into pieces of approximately 1 to 2 mm, and trypsinized for 3 hours at 378C (Trypsin EDTA 0.05%; Gibco, Carlsbad, Calif). Trypsin was neutralized with TNS (Lonza, Basel, Switzerland), and cells were filtered through a 40-mm nylon mesh. The obtained cells were seeded in 75-cm 2 plastic culture flasks and cultured in bronchial epithelial growth medium (Lonza). Medium was changed after 24 hours and every second day from then on. Cells were harvested at a confluence of 90% by means of trypsinization.
Tonsillar T-and B-cell, DC, and epithelial cell samples were used for IL15 mRNA measurements.
For cryopreservation, TMCs were resuspended in freezing medium (10% dimethyl sulfoxide and 45% FBS in complete RPMI 1640) and stored in liquid nitrogen until flow cytometric measurements, as well as ILC3 and B-cell isolations by using fluorescence-activated cell sorting.
Flow cytometry
For ILC3 measurements, 2.5 million cells were acquired by using flow cytometry. The minimum limit was 1 million cells. For readout measurements of coculture experiments, 20,000 to 50,000 cells were measured.
Establishment of the CD40L
1 ILC3-B-cell cocultures
All cell cultures were grown in RPMI 1640 medium supplemented with 1 mmol/L sodium pyruvate (Sigma), 1% MEM nonessential amino acids and vitamins (Sigma), 2 mmol/L L-glutamine (Sigma), 100 U/mL penicillin, 100 mg/mL streptomycin (Sigma), 100 mg/mL kanamycin (Gibco), and 10% heat-inactivated FCS (Sigma). Cells were cultured in 96-well plates at a concentration of 500 to 1000 cells/mL concentration.
L cells are mouse fibroblasts transfected with human CD40L and widely used as supporting cells in B-cell experiments. L cells express high levels of human CD40L on their surfaces and also release sCD40L. Irradiated L cells (75 Gy) at a concentration of 50,000/mL were used as controls in our experiments to compare the supporting characteristics and performance of an artificial and highly optimized coculturing cell (L-cell) with those of a biologically relevant cell type (CD40L 1 ILC3). For T-cell-B-cell cocultures,
CD3
1 CD4 1 T cells were sorted from the second blood sample of the same donor.
Proliferation and suppression assays B-cell proliferation was analyzed on (co-)culture day 12 by using flow cytometric detection of carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen, Carlsbad, Calif) dilution. The proliferative index is the median number of divisions the B cells have passed through since the beginning of the experiment. For ILC3 proliferation assays, we used CellTrace Violet (Molecular Probes, Eugene, Ore) and analyzed in the same way. Cells were stimulated with IL-15 (10 ng/mL; from PeproTech, Rocky Hills, NJ). In suppression assays rhIL-10 (10 ng/mL, PeproTech) was used in the control wells. Autologous CD3 
Analysis of cytokine and immunoglobulin production
Production of cytokines (IL-10, IL-1ra, IL-6, and sCD40L) and IgM was measured in cell-culture supernatants by using multiplex cytometric beadbased immunoassays (Bio-Plex System; Bio-Rad Laboratories, Hercules, Calif). Supernatants of various cultures were harvested on day 6 for cytokine and on day 12 for immunoglobulin measurements. Spontaneous cytokine and immunoglobulin secretion of the cells after the initial (day 1) CpG stimulation were detected, and it was not boosted by any further stimulation.
Quantitative real-time RT-PCR
Total RNA was extracted with the RNeasy Micro Kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. cDNA was synthesized with oligo-dT and reverse transcription reagents (Thermo Scientific, Waltham, Mass), according to the manufacturer's protocols. SYBR Green/ROX qPCR Master Mix (Bio-Rad Laboratories) was used for amplification of the PCR products. All primers were designed by us (listed in Table E1 ; purchased from Microsynth). Quantitative RT-PCR analysis was carried out on ABI Prism 7900HT instrument (Applied Biosystems, Foster City, Calif), and relative gene expression levels were calculated by using the comparative Ct (DDCt) method. All results were normalized to expression of EEF1A1 (encoding elongation factor 1a). tissues were embedded in OCT compound (Tissue-Tek; Sakura Finetek, Torrance, Calif), frozen in liquid nitrogen-cooled 2-methylbutane (Fluka), and stored at 2808C until cryosections were cut with an HM 500 OM Cryostat microtome (Mikrotom). Paraformaldehyde-fixed cryosections (7 mm) were sequentially incubated with the primary antibody, an Alexa Fluor dye-conjugated goat secondary antibody, and blocked with the isotype control antibody corresponding to the primary antibody. These staining cycle were repeated with all subsequent primary antibodies during the staining protocol. We developed 4-color immunofluorescence staining for detection RORgt
1
CD3
2 ILC3s and CD20 1 IL-10 1 Breg cells together in the same specimen. ILC3 detection was based on a previously reported approach.
E3
The following antibodies were used for ILC detection in tissue: anti-RORgt (AFKJS-9; eBioscience, San Diego, Calif) anti-CD161 (DX12, Becton Dickinson), anti-CD3 (CD3-12; Abd Serotec, Bio-Rad Laboratories), anti-CD40L (40804; R&D Systems, Minneapolis, Minn), anti-CD20 (EP459Y; Epitomics, Burlingame, Calif), anti-IL-10 (polyclonal goat, R&D Systems), and corresponding isotype control antibodies (from the same sources or DAKO, Glostrup, Denmark). Alexa Fluor dye-conjugated, species-and isotype-specific secondary antibodies (Invitrogen) were used for detection of bound primary antibodies.
Tissue sections were mounted with ProLong Gold antifade reagent with or without 49-6-diamidino-2-phenylindole dihydrochloride (DAPI; Invitrogen). Images were captured with a Leica TSC SPE confocal microscope with an ACS APO 633 1.3 OIL objective. Data were acquired by using Leica Application Suite Advance Fluorescence 2.4.1 software (Leica Microsystems). Brightness, contrast, and color balance of the pictures were adjusted in Imaris 7.7 image analysis software (Bitplane, Concord, Mass). Image panels were composed in Photoshop CS2. The general histology of palatine tonsils was demonstrated by staining the sections with hematoxylin and eosin. Fig E2, A and B, Lack of GATA3 (Fig E2, A) and TBX21 (Fig E2, B) mRNA expression of CD40L ILC3s sorted according to the gating strategy shown in Fig 1, A. TBX21 encodes T-bet. Total PBMCs and in vitro-differentiated T H 2 ( Fig E2, A) and T H 1 (Fig E2, B) cells were used as controls. *P < .01 versus PBMCs and CD40L 1 ILC3s. C, CD40L 1 ILC3s did not express GZMB and PRF1 mRNA encoding the cytotoxic enzymes granzyme B and perforin, respectively. CD40L 
Antibodies and viability dye
